Page header

Recommendation of the President – Jaypirca (pirtobrutinib)

On 30 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 49/2026 on the inclusion of the medicinal product Jaypirca (pirtobrutinib) in the reimbursement program B.12.FM: “Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)”

Publication in Public Information Bulletin (BIP) >>